Pancreatic Cancer Research

ResearcherKyushu UniversityActive in the last 2 years

Hiroshi Ishii

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3295-4867; OpenAlex author ID A5057311746. Sources: OpenAlex.

Their work

Papers
40 (first author 2, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
160
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 2 papers · 2014: 3 papers · 2015: 4 papers · 2016: 2 papers · 2017: 4 papers · 2018: 5 papers · 2019: 2 papers · 2020: 3 papers · 2021: 2 papers · 2022: 3 papers · 2023: 2 papers · 2024: 1 paper · 2025: 1 paper · 2026: 4 papers

Papers 40

  1. Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis of the GENESECT study. Co-author DOI 10.1002/bcp.70611↗
  2. Plasma Protein Biomarkers for Early Detection of Pancreatic Cancer. Co-author DOI 10.1002/ijc.70637↗
  3. Association between ABCB1 genetic polymorphisms with treatment outcomes in patients with metastatic pancreatic cancer. Co-author DOI 10.1007/s10147-026-03201-0↗
  4. Associations Between Obesity, Diabetes Mellitus, and Pancreatic Cancer in the Japanese Population: A Mendelian Randomization Study. Co-author DOI 10.1111/cas.70344↗
  5. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  6. Pharmacogenomic study of gemcitabine efficacy in patients with metastatic pancreatic cancer: A multicenter, prospective, observational cohort study (GENESECT s… Co-author DOI 10.1002/cncr.35343↗
  7. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). Co-author DOI 10.1016/j.ejca.2022.12.014↗
  8. Effect of systemic inflammatory response on induction chemotherapy followed by chemoradiotherapy for locally advanced pancreatic cancer: an exploratory subgrou… Co-author DOI 10.1093/jjco/hyad044↗
  9. Endoscopic duodenal stent placement versus gastrojejunostomy for unresectable pancreatic cancer patients with duodenal stenosis before introduction of initial … Co-author DOI 10.1093/jjco/hyab194↗
  10. Management of elderly patients with unresectable pancreatic cancer. Co-author DOI 10.1093/jjco/hyac101↗
  11. Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer. Last author DOI 10.1093/oncolo/oyac157↗
  12. Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group… Last author DOI 10.1093/jjco/hyaa198↗
  13. Impact of Renal Function on S-1 + Radiotherapy for Locally Advanced Pancreatic Cancer: An Integrated Analysis of Data From 2 Clinical Trials. Co-author DOI 10.1097/mpa.0000000000001879↗
  14. nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients. Co-author DOI 10.1002/cam4.3558↗
  15. Genome-wide association meta-analysis identifies GP2 gene risk variants for pancreatic cancer. Co-author DOI 10.1038/s41467-020-16711-w↗
  16. ABO Blood Type and the Long-term Outcomes of Pancreatic Cancer. Co-author DOI 10.2169/internalmedicine.3748-19↗
  17. Early Detection of Pancreatic Cancer in Patients With Chronic Liver Disease Under Hepatocellular Carcinoma Surveillance. Co-author DOI 10.1016/j.mayocp.2018.12.034↗
  18. Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer. Co-author DOI 10.1038/s41598-019-52486-x↗
  19. A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer. First author DOI 10.1007/s00280-018-3577-9↗
  20. Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic … Co-author DOI 10.1016/j.pan.2018.07.007↗
  21. SLCO1B1 Polymorphism Is a Drug Response Predictive Marker for Advanced Pancreatic Cancer Patients Treated With Gemcitabine, S-1, or Gemcitabine Plus S-1. Co-author DOI 10.1097/mpa.0000000000001052↗
  22. A randomised controlled trial of gemcitabine hydrochloride plus S-1 combination therapy versus gemcitabine hydrochloride therapy alone in pancreatic cancer pat… Co-author DOI 10.1136/bmjgast-2017-000187↗
  23. Prediction model for pancreatic cancer risk in the general Japanese population. Co-author DOI 10.1371/journal.pone.0203386↗
  24. Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients. Co-author DOI 10.1002/ijc.30510↗
  25. Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patien… Co-author DOI 10.1007/s00280-017-3250-8↗
  26. A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gem… Co-author DOI 10.1007/s00280-017-3351-4↗
  27. Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data. Co-author DOI 10.1038/bjc.2017.128↗
  28. Carbon Ion Radiation Therapy With Concurrent Gemcitabine for Patients With Locally Advanced Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2015.12.362↗
  29. Associations between polymorphisms in folate-metabolizing genes and pancreatic cancer risk in Japanese subjects. Co-author DOI 10.1186/s12876-016-0503-7↗
  30. Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer. Co-author DOI 10.1038/bjc.2015.103↗
  31. Genome-wide association study-identified SNPs (rs3790844, rs3790843) in the NR5A2 gene and risk of pancreatic cancer in Japanese. Co-author DOI 10.1038/srep17018↗
  32. Prognostic value of neutrophil-lymphocyte ratio and level of C-reactive protein in a large cohort of pancreatic cancer patients: a retrospective study in a sin… Last author DOI 10.1093/jjco/hyu159↗
  33. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study. Co-author DOI 10.1111/cas.12674↗
  34. Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies. First author DOI 10.1002/jhbp.130↗
  35. Lack of associations between genetic polymorphisms in GSTM1, GSTT1 and GSTP1 and pancreatic cancer risk: a multi-institutional case-control study in Japan. Co-author DOI 10.7314/apjcp.2014.15.1.391↗
  36. [FOLFIRINOX-induced hyperammonemic encephalopathy in a patient with pancreatic cancer]. Co-author PMID 25373377↗
  37. A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer. Co-author DOI 10.1016/j.ijrobp.2012.03.059↗
  38. Association between variations in the fat mass and obesity-associated gene and pancreatic cancer risk: a case-control study in Japan. Co-author DOI 10.1186/1471-2407-13-337↗
  39. Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinic… Co-author DOI 10.1007/s00280-012-1822-1↗
  40. An overview of genetic polymorphisms and pancreatic cancer risk in molecular epidemiologic studies. Co-author DOI 10.2188/jea.je20100090↗

Closest collaborators

The 25 strongest of 160 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Makoto Ueno · 20 shared papers, 2011–2026 · strength 1.92
  2. Masato Ozaka · 18 shared papers, 2012–2026 · strength 1.88
  3. Junji Furuse · 15 shared papers, 2013–2023 · strength 1.38
  4. Satoshi Kobayashi · 9 shared papers, 2018–2026 · strength 1.27
  5. Takuji Okusaka · 16 shared papers, 2013–2026 · strength 1.24
  6. Naoki Sasahira · 7 shared papers, 2018–2026 · strength 1.23
  7. Masafumi Ikeda · 13 shared papers, 2013–2023 · strength 1.02
  8. Nobumasa Mizuno · 9 shared papers, 2015–2023 · strength 0.80
  9. Naoto Egawa · 10 shared papers, 2011–2026 · strength 0.70
  10. Tatsuya Ioka · 9 shared papers, 2013–2023 · strength 0.67
  11. Yingsong Lin · 8 shared papers, 2011–2026 · strength 0.65
  12. Shogo Kikuchi · 8 shared papers, 2011–2026 · strength 0.65
  13. Daiki Tsuji · 3 shared papers, 2024–2026 · strength 0.63
  14. Takashi Yokokawa · 3 shared papers, 2024–2026 · strength 0.63
  15. Ken-ichi Suzuki · 3 shared papers, 2024–2026 · strength 0.63
  16. Masahiro Hatori · 3 shared papers, 2024–2026 · strength 0.63
  17. Kunihiko Itoh · 3 shared papers, 2024–2026 · strength 0.63
  18. Naohiro Okano · 5 shared papers, 2021–2023 · strength 0.55
  19. Shinichi Ohkawa · 10 shared papers, 2014–2018 · strength 0.49
  20. Masahiro Nakatochi · 3 shared papers, 2018–2026 · strength 0.48
  21. Akiko Todaka · 4 shared papers, 2021–2023 · strength 0.44
  22. Yasushi Adachi · 2 shared papers, 2026 · strength 0.42
  23. Keitaro Matsuo · 6 shared papers, 2013–2026 · strength 0.39
  24. Shoji Nakamori · 5 shared papers, 2015–2021 · strength 0.38
  25. Masayuki Furukawa · 4 shared papers, 2015–2023 · strength 0.36

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.